Asia-Pacific Health Screening Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: Asia-Pacific Health Screening Market

Asia-Pacific health screening market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 13.6% in the forecast period of 2021 to 2028 and is expected to reach USD 109,704.00 million by 2028. The rising number of chronic diseases, geriatric population, and increasing awareness about early detection and treatment of disease are the major drivers that propelled the market's demand in the forecast period.

Health screening is an important method of early detection of a specific disorder. The screening tests are often used in preventative medicine to identify whether an individual shows early signs of a condition's risk factors. The disease, which may be detected by screening includes cancer, diabetes, high cholesterol, high blood pressure, and osteoporosis.

The rising awareness among people about early detection and treatment of disease and increasing health expenditure are increasing the demand for health screening.

Rising demand for health screening because of its efficacy, along with growing number of service providers, and increasing awareness campaign by private and public players of health screening are propelling the growth of the health screening market in the forecast period. However, the high cost of screening test may hamper the market growth in the forecast period.

The Asia-Pacific health screening market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Health Screening Market Scope and Market Size

Asia-Pacific health screening market is segmented into eight notable segments based on test type, package type, panel type, sample type, technology, condition, sample collection sites, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

• On the basis of test type, Asia-Pacific health screening market is segmented into cholesterol tests, diabetes test, cancer screening, general checkup test, STDs, blood pressure test, and others. In 2021, the cholesterol test segment is expected to dominate the market because of rise in geriatric population and sedentary lifestyle.
• On the basis of package type, the Asia-Pacific health screening market is segmented into basic health screening, senior citizen profile, women health check, men health check, heart check, diabetes check, and others. In 2021, basic health screening segment is expected to dominate the market because of increasing healthcare expenditure in Asian countries.
• On the basis of panel type, Asia-Pacific health screening market is segmented into multi-test panels and single-test panels. In 2021, multi-test panels segment is expected to dominate the market due to the technological advancement of laboratories in this region
• On the basis of sample type, the Asia-Pacific health screening market is segmented into blood, urine, serum, saliva, and others. In 2021, blood segment is expected to dominate the market because it is the most type of sample and can diagnosed in almost every laboratory.
• On the basis of technology, the Asia-Pacific health screening market is segmented into immunoassays, medical imaging, QPCR (Quantitative Polymerase Chain Reaction), Q-FISH (Quantitative Fluorescence, in situ hybridization), TRF (Terminal Restriction Fragment), STELA (Single Telomere Length Analysis), and others. In 2021, immunoassays segment is expected to dominate the market because the Asian market is one of the emerging healthcare market with growing medical tourism which is expected to increase the demand for all screening technique in this reason
• On the basis of condition, the Asia-Pacific health screening market is segmented into cardiovascular disease, metabolic disorders, cancer, inflammatory conditions, musculoskeletal disorders, neurological conditions, Hepatitis-C complications, immunology-related conditions, and others. In 2021, cardiovascular disease segment is expected to dominate the market because of high prevalence of cardiovascular diseases in this region also
• On the basis of sample collection sites, the Asia-Pacific health screening market is segmented into hospitals, homes, diagnostic laboratories, offices, and others. In 2021, hospitals segment is expected to dominate the market as the infrastructure is growing in Asia-pacific region with increasing hospitals numbers
• On the basis of distribution channel, the Asia-Pacific health screening market is segmented into direct tenders, retail sales, and others. In 2021, direct tender segment is expected to dominate the market because of increase in overall sales of health screening programs.

 Asia-Pacific Health Screening Market Country Level Analysis

Asia-Pacific health screening market is analyzed, and market size information is provided on the test type, package type, panel type, sample type, technology, condition, sample collection sites, and distribution channel.

The countries covered in the Asia-Pacific health screening market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific. India in the Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of innovative R&D and new product launches and approvals.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Rise in Geriatric Population and Increased Incidence of Cancer and CVD Diseases are Boosting the Market Growth of Asia-Pacific Health Screening Products 

Asia-Pacific health screening market also provides you with detailed market analysis for every country's growth in the health screening product industry with drugs sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the Health Screening market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and Asia-Pacific Health Screening Market Share Analysis

The Asia-Pacific health screening market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Asia-Pacific health screening market.

The major companies which are dealing in the Asia-Pacific health screening market are Sonic Healthcare Limited, Quest Diagnostics Incorporated, Healius Limited, Quidel Corporation, Eurofins Scientific, GRAIL, , Exact Sciences Corporation, SYNLAB International GmbH, UNILABS, LabPLUS, BioReference Laboratories, , ACM Global Laboratories, Cerba Healthcare, , Innova Medical Group, AMEDES Holding GmbH, RadNet, Inc., Natera, Inc., Trinity Biotech, Nuffield Health, RepeatDx, NeoGenomics Laboratories, H.U Group Holdings, Inc., Lifelabs, ARUP Laboratories, Q2 Solutions, Genova Diagnostics, Life Length, DNA Labs India, , Telomere Diagnostics, Charles River Laboratories, Ambry Genetics, SpectraCell Laboratories, Inc., Dr. Lal PathLabs, and Laboratory Corporation of America among others.

Many product launch and agreement are also initiated by the companies’ worldwide, which also accelerates the Asia-Pacific health screening market.

For instance,

• In March 2020, Sonic healthcare announced that they have acquired Pathologie Hamburg- a pathology practice laboratory. This acquisition has provided the company with increased production and testing capabilities.In September2020, Healius Limited announced that it gone into sales agreement with Virtus Health to acquire adora Fertility. This will boost the market for the company in the forecast period.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the Health Screening market which also provides the benefit for organization to improve their offering for Health Screening.

SKU-66235